侵袭性肺曲霉菌感染患者使用伏立康唑致视觉模糊1例分析

Abstract
Figure/Table
References (17)
Related Citation (1)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract

In this article,one patient with Invasive pulmonary aspergillus infection treated by Voriconazole in department of respiratory medicine of our hospital was selected and the reason of visual blur caused by Voriconazole was analyzed on the basis of excluding all kinds of mental disorders and metabolic encephalopathy before voriconazole treatment.To this type of patients,Volcicconazole can be continued to be selected when other drugs against Invasive pulmonary aspergillus infection can not effectively control the patients′condition,but it is necessary to adjust the dosage of drugs and monitor closely when the drug was used to ensure the rationality and safety of the clinical medication.

Key words： Invasive pulmonary aspergillus Voricionazole Visual blur

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Yun

Cite this article:

LIU Yun. A case analysis of visual blur caused by Voriconazole in the treatment of patients with Invasive pulmonary aspergillus infection[J]. 中国当代医药, 2018, 25(18): 158-160.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I18/158

[1]	Pini G，Faggi E，Donato R，et al.Invasive pulmonary aspergillosis in neutropenic patients and the influence of hospital renovation[J].Mycoses，2015，51（3）：117-122.
[2]	朱静.伏立康唑的药理特性及临床应用[J].天津药学，2007，19（4）：48-50.
[3]	Johnson LB，Kauffman CA.Voriconazole：a new triazole antifugal agent[J].Clin Infect Dis，2003，36（5）：630-637.
[4]	曹永兵，张磊，王彦，等.伏立康唑及其临床应用[J].中国新药与临床杂志，2005，24（4）：330-332.
[5]	中华医学会重症医学分会.重症患者侵袭性真菌感染诊断与治疗指南（2007）[J].中华内科杂志，2007，46（11）：960-966.
[6]	Kinoahita J，Iwata N，Ohba M，et al.Mechanism of voriconazole induced transient visual disturbances：reversible dysfunction of retinal ON-bipolar cells in monkeys[J].Invest Ophthalmol Vis Sci，2011，52（8）：5058-5063.
[7]	Chu HY，Jain R，Xie H，et al.Voriconazole therapeutic drug monitoring：retrospective cohort study of the relationship to clinical outcomes and adverse events[J].BMC Infect Dis，2013，13（1）：105.
[8]	汪复，张婴元.实用抗感染治疗学[M].北京：人民卫生出版社，2013：491-492.
[9]	王冬，曹江，江学维，等.伏立康唑致视觉障碍的文献计量学研究[J].药物不良反应杂志，2013，15（6）：325-329.
[10]	Pestka EL，Hale AM，Johnson BL，et al.Cytochrome P450 testing for better psychiatric care[J].J Psychosoc Nurs Ment Health Serv，2007，45（10）：15-18.
[11]	Wang G，Lei HP，Li Z，et al.The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers[J].Eur J Clin Pharmacol，2009，65（3）：281-285.
[12]	雷和平，周宏灏.伏立康唑的药代动力学及其与其他药物间的相互作用[J].实用医学杂志，2008，24（11）：2011-2013.
[13]	Lee S，Kim B H，Nam WS，et al.Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers[J].J Chin Pharmacol，2012，52（2）：195-203.
[14]	Wang T，Chen S，Sun J，et al.Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections[J].J Antimicrob Chemother，2014，69（2）：463-470.
[15]	Liu P，Mould DR.Population pharmacokinetic analysis of voriconzole and anidulafungin in adult patients with invasive aspergillosis[J].Antimicrob Agents Chemother，2014，58（8）：4718-4726.
[16]	Wang T，Zhu H，Sun J，et al.Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens on patients with invasive fungal infections[J].Int J Antimicrob Agents，2014，44（5）：436-442.
[17]	中华医学会呼吸病学分会感染学组.肺真菌病诊断和治疗专家共识 [J].中华结核和呼吸杂志，2015，11（30）：821-834.